ERGIC2

Across TCGA pan-cancer cohorts, ERGIC2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ERGIC2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ERGIC2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ERGIC2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC and PDAC are the cancer types where ERGIC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.629	1.000	.002	48	view →
PDAC	OS	Tertile	IV	0.973	0.490	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ERGIC2–CCRCC (OS)

Open the CCRCC breakdown →